Nektar Therapeutics
NKTR
Market Cap$105.58M
Close$
$-5.72
119.6% downside
Current Fair Value
119.6% downsideOvervalued by 119.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $105.58 Million |
|---|---|
| Enterprise Value | $167.03 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.58 |
| Beta | 0.56 |
| Outstanding Shares | 210,924,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -13.49 |
|---|---|
| PEG | -35.26 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.91 |
| Enterprise Value to EBIT | -1.7 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.6 |
| Debt to Equity | 7.3 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Nektar Therapeutics
CEO: Howard Robin